Elsevier

Brain Research

Volume 402, Issue 2, 3 February 1987, Pages 269-274
Brain Research

Research report
Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice

https://doi.org/10.1016/0006-8993(87)90033-3Get rights and content

Abstract

The histochemical, biochemical and behavioural consequences of MPTP administration in C-57 black mice was assessed 0.5 h, 24 h and 7 days after the last injection of this drug administered daily for 10 days during a 12 day period (30 mg/kg/injection or vehicle). A slight but significant impairment of open field performance was observed at 0.5 h after the last injection of MPTP while a facilitation of locomotory behaviour was observed only in the 24 h post-injection group. Striatal dopamine levels were reduced to 14, 18 and 27% of control levels in the 0.5 h, 24 h and 7 day post-MPTP treated groups, respectively. Histochemical assessment was in agreement with the biochemical assay results in that all MPTP treated animals showed severe depletion of striatal terminal fields. Other terminal fields were occasionally affected by MPTP treatment and only rarely was any change in the fluorescence or morphology of nigral cell bodies seen. Accumulation of amines in the degenerating amine-containing axons which traverse the lateral hypothalamus was not seen in any of the MPTP treated animals. These results indicate that, in the C-57 black mouse, MPTP causes a depletion of striatal dopamine without causing nigral cell loss or axon swelling as is observed with other experimental treatments such as 6-hydroxydopamine. Consistent with this is the behavioural data, indicating that severe deficits in motor function which are associated with nigrostriatal cell loss were not seen. We conclude that the inability of MPTP to produce motor function impairment in various species is related to its failure to produce true degenerative changes in nigrostriatal neurons which include amine accumulation in the degenerating axons and cell loss in the substantia nigral complex.

References (24)

Cited by (67)

  • Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson's disease in mice

    2019, Life Sciences
    Citation Excerpt :

    The pathologic conditions of PD can be created by MPTP administration in animals to make them as experimental PD models which exhibit odd behavioral changes and pathophysiological features of neurodegenerative disorders, including oxidative stress, dopaminergic neurodegeneration and neuroinflammation-mediated glial cell activation [24,25]. Previous studies also showed that the MPTP administration to rodents and primates induce DA neuron loss in SNpc and cause depleted a DA level which leads to severe motor dysfunction [26]. In the present study, we investigated the neuroprotective role of PHL in MPTP induced degeneration of dopaminergic neurons which is well elucidated through enhanced DA levels, improved behavioral impairments, inhibition of glial cell activation and suppression of inflammatory responses in the mice of experimental groups treated with PHL.

  • Hederagenin and α-hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice

    2017, Pharmacological Research
    Citation Excerpt :

    For example, while there was literature reporting the long lasting motor deficit in mice after toxin administration [83,84], there were reports depicting the restoration of motor function [85]. It is also noted worthy that there were literatures reporting no changed or hyperactive locomotion in mice after MPTP injection [37,86]. In summary, by depicting the protective role of autophagy in facilitating the degradation of neurodegenerative disease proteins such as α-syn and huntingtin, our study has provided novel insight into the drug discovery of autophagic inducers from traditional Chinese medicinal plants, and suggested the possible molecular mechanisms and therapeutic role of the newly identified active components, hederagenin and α-hederin, from HH in modulating PD or HD.

  • Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein

    2013, NeuroToxicology
    Citation Excerpt :

    Despite these differences in DA reuptake mechanisms, the cellular machinery responsible for DA synthesis, storage, release and catabolism are similar in both NSDA and TIDA neurons. The differential susceptibility of TIDA and NSDA neurons to PD-associated cellular pathology has also been observed in neurotoxicant-based animal models of PD (Willis and Donnan, 1987; Mogi et al., 1988; Sundstrum et al., 1990; Behrouz et al., 2007; Benskey et al., 2012). Despite inherent limitations, neurotoxicant-based models of PD accurately recapitulate many of the key molecular pathological features associated with PD, including mitochondrial dysfunction, oxidative stress, impairment of ubiquitin proteasome pathway (UPP) function, activation of programmed cell death, and neuroinflammation (Zang and Misra, 1993; Jackson-Lewis et al., 1995; Petroske et al., 2001; Dauer and Przedborski, 2003; Hoglinger et al., 2003; Przedborski et al., 2004; Fornai et al., 2005; Chan et al., 2006).

  • Neurotoxin-based models of Parkinson's disease

    2012, Neuroscience
    Citation Excerpt :

    The second important aspect is that, after recovering from the injections, mice look normal, meaning that highly challenging behavioral test are required to unravel some of the deficits they may display. Indeed, MPTP-intoxicated mice exhibit a remarkable capacity for functional recovery, for which reason some motor impairments are only transient in nature (Willis and Donnan, 1987; Sedelis et al., 2001). Finally, as motor impairment is correlated with the lesion magnitude, it is therefore more difficult to conduct behavioral tests in the case of moderate lesions of the dopaminergic system.

View all citing articles on Scopus
View full text